HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Richter, M. V. Articles by Topham, D. J. Search for Related Content PubMed PubMed Citation Articles by Richter, M. V. Articles by Topham, D. J.

The ₁₁ Integrin and TNF Receptor II Protect Airway CD8⁺ Effector T Cells from Apoptosis during Influenza Infection¹

Department of Microbiology and Immunology and the David H. Smith Center for Vaccine Biology and Immunology, Aab Institute of Biomedical Sciences, University of Rochester, Rochester, NY 14642

Primary viral infections of the lung induce potent effector CD8 T cell responses. To function in the influenza-infected airways, CD8 T cells must be able to resist cell death. The majority of the CD8 T cells in the airways and lung parenchyma expressed CD49a, the -chain of the type IV collagen receptor VLA-1, and these cells were highly activated, producing both IFN- and TNF-. In the airways, where type IV collagen is abundant, but not the spleen, the CD49a⁺ CD8 cells had reduced proportions of annexin V and caspase 8, and >80% expressed the TNF- receptor II, while Fas, TNFR-I, and CD27 expression were similar to CD49a^– cells. Furthermore, the CD49a⁺, but not CD49a^–, CD8 T cells from the airways were resistant to active induction of apoptosis in the presence of type IV collagen and TNF- in vitro. We propose that TNFR-II and the VLA-1 synergize to protect effector CD8 T cells in the infected airways from apoptosis during the acute infection.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ This work was supported by National Institutes of Health Grants AG021970 and AI050020.

² Address correspondence and reprint requests to Dr. David J. Topham, David H. Smith Center for Vaccine Biology and Immunology, Aab Institute of Biomedical Sciences, University of Rochester Medical Center, 601 Elmwood Avenue, Box 609, Rochester, NY 14642. E-mail address: david_topham{at}urmc.rochester.edu

³ Abbreviations used in this paper: cMEM, complete MEM; BAL, bronchoalveolar lavage; 7AAD, 7-aminoactinomycin D; NP, nucleoprotein; TRAF, TNFR-associated factor; DD, death domain; DISC, death-inducing signal complex.